Boxiong Xie

Safety and effectiveness of neoadjuvant PD-1 inhibitor (toripalimab) plus chemotherapy in stage II–III NSCLC (LungMate 002): an open-label, single-arm, phase 2 trial

Xinsheng Zhu, Liangdong Sun, Nan Song et al. · BMC Medicine · 2022 · 67 citations · Full text

Medicine, Oncology, Pharmacology +17

Single-port video-assisted thoracic surgery in 1063 cases: a single-institution experience

Dong Xie, Haifeng Wang, Ke Fei et al. · European Journal of Cardio-Thoracic Surgery · 2016 · 64 citations · Full text

Medicine, Surgery, Cardiothoracic Surgery +15

Exosomes derived from M2 type tumor-associated macrophages promote osimertinib resistance in non-small cell lung cancer through MSTRG.292666.16-miR-6836-5p-MAPK8IP3 axis

Xiaoying Wan, Boxiong Xie, Hui Sun et al. · Cancer Cell International · 2022 · 54 citations · Full text

Medicine, Oncology, Pharmacology +17

[Shanghai Pulmonary Hospital Experts Consensus on the Management of Ground-Glass Nodules Suspected as Lung Adenocarcinoma (Version 1)].

Gening Jiang, Chang Chen, Yuming Zhu et al. · PubMed · 2018 · 46 citations · Full text

Medicine, Oncology, Surgery +17

Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients

Qinfang Deng, Boxiong Xie, Leilei Wu et al. · Heliyon · 2018 · 41 citations · Full text

Medicine, Molecular Biology, Oncology +17